




1652\$

<b>AMENDMENT TRANSMITTAL LETTER (Large Entity)</b>			Docket No. 112843-006		
Applicant(s): Maurer et al.					
Serial No. 09/674,738	Filing Date July 25, 2001	Examiner M. Walicka	Group Art Unit 1652		
Invention: <b>USE OF BROMELAINE PROTEASES FOR INHIBITING BLOOD COAGULATION</b>					
<b>TO THE ASSISTANT COMMISSIONER FOR PATENTS:</b>					
Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.					
<b>CLAIMS AS AMENDED</b>					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	6 -	6 =	0 x	\$18.00	\$0.00
INDEP. CLAIMS	2 -	1 =	1 x	\$84.00	\$84.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT</b>					<b>\$84.00</b>
<div><input type="checkbox"/> No additional fee is required for amendment.</div> <div><input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ A duplicate copy of this sheet is enclosed.</div> <div><input checked="" type="checkbox"/> A check in the amount of <b>\$84.00</b> to cover the filing fee is enclosed.</div> <div><input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. <b>02-1818</b> A duplicate copy of this sheet is enclosed.</div> <div><input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16.</div> <div><input type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.</div>					
 _____ <i>Signature</i>		Dated: <b>March 18, 2003</b>			
<b>Robert M. Barrett</b> <b>Reg. No. 30,142</b> <b>BELL, BOYD &amp; LLOYD LLC</b> <b>P.O. Box 1135</b> <b>Chicago, IL 60690-1135</b> <b>Phone: 312-807-4204</b>					
<div><div>I certify that this document and fee is being deposited on 03-18-2003 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.</div><div> <i>Signature of Person Mailing Correspondence</i></div><div><b>Robert J. Buccieri</b> <i>Typed or Printed Name of Person Mailing Correspondence</i></div></div>					
cc:					



RECEIVED  
MAR 31 2003  
TECH CENTER 1600/2900



#16/B  
DPT  
4-1-03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Maurer et al.  
Appl. No.: 09/674,738  
Conf. No.: 5329  
Filed: July 25, 2001  
Title: USE OF BROMELAINE PROTEASES FOR INHIBITING BLOOD COAGULATION  
Art Unit: 1652  
Examiner: M. Walicka  
Docket No.: 112843-006

TECH CENTER 1600/2900

MAR 31 2003

RECEIVED

Commissioner for Patents  
Washington, DC 20231

RECEIVED

MAR 31 2003

RESPONSE TO OFFICE ACTION

TECH CENTER 1600/2900

Sir:

In response to the Office Action dated December 18, 2003, please amend the above-identified patent application as follows:

In the Specification:

Please substitute the Title with the following rewritten Title:

USE OF BROMELAINE PROTEASES FOR INHIBITING BLOOD COAGULATION

Please substitute the paragraph beginning on page 1 at line 13 with the following rewritten paragraph:

B1  
Bromelaine is a mixture of quite different proteins that may be isolated from plants of the family Bromeliaceae, the exact composition of which could so far not yet be completely characterized due to the complexity and variety of the components contained therein. It could, however, be shown that bromelaine contains different phosphatases, cellulases, glycosidases, cysteine proteases and the peptide inhibitors thereof, as well as additional not yet more closely identified components. The material and quantitative composition of bromelaine, however, varies in response to the origin and the isolation procedure from the respective source, so that different methods for isolating the raw product, for standardizing the same as well as for purifying specific components contained therein, have been developed. As used herein, the term "bromelaine" or other like terms is meant to be interchangeable with term "bromelain."

03/27/2003 CNGUYEN 00000080 021818 09674738

01 FC:1201 84.00 CH